How do the new RxPONDER results affect your choice of adjuvant therapy for postmenopausal women with HR+/HER2 negative breast cancer and 1-3 positive lymph nodes?  

The RxPonder trial results show that in postmenopausal women with 1-3 positive nodes and recurrence scores under or equal to 25, there was no benefit for chemotherapy added to endocrine therapy versus endocrine therapy alone. Whereas, for those with recurrence of 26 or above, I would offer chemother...